Is RARE a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Ultragenyx Pharmaceutical (RARE) rests on Near-term gene therapy approvals: Two gene therapies are under FDA review with 2026 decision dates: DTX401 for glycogen storage disease type Ia and UX111 for Sanfilippo syndrome type A. The bear case rests on ultragenyx remains unprofitable, with a net loss of about $575 million in 2025 and roughly $737 million of cash as of December 2025, so continued spending or delayed approvals could pressure the balance sheet and raise dilution or financing risk. Analysts covering it publish targets from $27.00 to $96.00 against a $25.87 price, so even the professionals disagree by 129% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Ultragenyx Pharmaceutical (NASDAQ: RARE) develops and sells treatments for rare and ultra-rare genetic diseases, conditions with small patient populations and often no approved therapy. Its commercial base includes Crysvita for X-linked hypophosphatemia (its largest product), Dojolvi for long-chain fatty acid oxidation disorders, Evkeeza, and Mepsevii, which together produced about $673 million of revenue in 2025. The company spans multiple modalities, protein-replacement, small molecule, antisense, and gene therapy, and is preparing several late-stage programs for potential approval. The investment picture is that of a growing but still loss-making specialty biotech. Revenue grew roughly 20% in 2025, yet the company posted a net loss of about $575 million as it funds heavy R&D. Management has reaffirmed 2026 revenue guidance of $730 million to $760 million and reiterated a goal of reaching profitability in 2027, contingent on commercial growth, expense discipline, and monetizing potential priority review vouchers. The stock therefore trades largely on pipeline catalysts and the credibility of that profitability timeline rather than on current earnings.
The bull case: what would have to be true for $96.00
The most optimistic published target on RARE is $96.00, +271.1% from the $25.87 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Near-term gene therapy approvals
Two gene therapies are under FDA review with 2026 decision dates: DTX401 for glycogen storage disease type Ia and UX111 for Sanfilippo syndrome type A. Both target diseases with no approved therapies, giving Ultragenyx a potential first-mover position. Approvals could also unlock sellable priority review vouchers that management is counting on for cash.
2. Angelman syndrome readout
Pivotal Phase 3 Aspire data for GTX-102 in Angelman syndrome is expected in the second half of 2026. Angelman is a large opportunity relative to Ultragenyx's typical ultra-rare markets, so a positive readout would materially expand the addressable pipeline. It is also one of the highest-risk binary events on the calendar.
3. Growing commercial base
Crysvita, guided to roughly $500 million to $520 million in 2026, anchors a portfolio that management expects to keep growing at a high-single to low-double-digit rate. A steady base business helps fund the pipeline and supports the stated 2027 profitability target. Dojolvi and Evkeeza add incremental, if smaller, contribution.
4. Cost discipline toward profitability
Ultragenyx cut about 10% of its workforce and guided 2026 R&D and SG&A to be flat-to-down as it concentrates resources on near-term launches. The restructuring is meant to preserve cash and make the 2027 profitability goal credible. Execution on this cost curve is central to the equity story.
The bear case: what would have to be true for $27.00
The most pessimistic published target is $27.00, +4.4% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Ultragenyx Pharmaceutical is worth if the risks below bite instead of the drivers above.
Ultragenyx remains unprofitable, with a net loss of about $575 million in 2025 and roughly $737 million of cash as of December 2025, so continued spending or delayed approvals could pressure the balance sheet and raise dilution or financing risk. The value concentrated in binary regulatory and clinical events (DTX401, UX111, and especially the GTX-102 Angelman readout) means a single negative outcome could sharply move the stock. Rare-disease revenue depends on small patient counts, payer reimbursement, and diagnosis rates, all of which can disappoint. The company faces well-capitalized competitors in gene therapy and orphan drugs, including BioMarin, Sarepta, and larger players. Finally, the 2027 profitability target is a management objective, not a guarantee, and could slip.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding RARE already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on RARE
19 analysts cover RARE, with an average target of $53.37 (+106.3% against $25.87) and a split of 17 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the RARE forecast and price target page.
How is RARE valued? (as of MAY 2026)
Snapshot for RARE as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$670M
- FY2025 revenue: ~$673M (up ~20%)
- Q1 2026 revenue: ~$136M
- FY2025 net loss: ~$575M
- Cash and marketable securities: ~$737M (Dec 2025)
- Market cap: ~$2.6B
Ultragenyx trades at a modest multiple of revenue for a biopharma but has no earnings, so conventional P/E valuation does not apply. The market is effectively pricing the pipeline and the credibility of the 2027 profitability goal. Guidance for 2026 revenue is $730 million to $760 million, which excludes any potential new product launches.
How do you decide if RARE is a buy?
Rather than asking whether RARE is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold RARE indirectly through an index or sector ETF before adding more.
What would change your mind on RARE
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Near-term gene therapy approvals stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: ultragenyx remains unprofitable, with a net loss of about $575 million in 2025 and roughly $737 million of cash as of December 2025, so continued spending or delayed approvals could pressure the balance sheet and raise dilution or financing risk fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the RARE stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about RARE against your real portfolio and see your actual exposure before deciding.
Investing in Ultragenyx Pharmaceutical with AI
Connect the broker you already use and ask Walnut's AI how RARE fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is RARE a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Near-term gene therapy approvals, with revenue (ttm) at ~$670M. The bear case rests on ultragenyx remains unprofitable, with a net loss of about $575 million in 2025 and roughly $737 million of cash as of December 2025, so continued spending or delayed approvals could pressure the balance sheet and raise dilution or financing risk. Analysts covering it are spread from $27.00 to $96.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell RARE?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Ultragenyx remains unprofitable, with a net loss of about $575 million in 2025 and roughly $737 million of cash as of December 2025, so continued spending or delayed approvals could pressure the balance sheet and raise dilution or financing risk. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $27.00, +4.4% from the $25.87 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for RARE?
+
Near-term gene therapy approvals. Two gene therapies are under FDA review with 2026 decision dates: DTX401 for glycogen storage disease type Ia and UX111 for Sanfilippo syndrome type A. The most optimistic analyst target on RARE is $96.00, +271.1% from the $25.87 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for RARE?
+
Ultragenyx remains unprofitable, with a net loss of about $575 million in 2025 and roughly $737 million of cash as of December 2025, so continued spending or delayed approvals could pressure the balance sheet and raise dilution or financing risk. The value concentrated in binary regulatory and clinical events (DTX401, UX111, and especially the GTX-102 Angelman readout) means a single negative outcome could sharply move the stock. Rare-disease revenue depends on small patient counts, payer reimbursement, and diagnosis rates, all of which can disappoint. The company faces well-capitalized competitors in gene therapy and orphan drugs, including BioMarin, Sarepta, and larger players. Finally, the 2027 profitability target is a management objective, not a guarantee, and could slip. The most pessimistic published target is $27.00, +4.4% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Ultragenyx Pharmaceutical do?
+
Ultragenyx Pharmaceutical (NASDAQ: RARE) develops and sells treatments for rare and ultra-rare genetic diseases, conditions with small patient populations and often no approved the
What would have to change for RARE to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Near-term gene therapy approvals) stalling in the reported numbers rather than in the narrative, the risk above (ultragenyx remains unprofitable, with a net loss of about $575 million in 2025 and roughly $737 million of cash as of December 2025, so continued spending or delayed approvals could pressure the balance sheet and raise dilution or financing risk) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Ultragenyx do?
+
Ultragenyx develops and commercializes treatments for rare and ultra-rare genetic diseases. It sells four approved products, led by Crysvita, and is advancing several late-stage gene therapies and other candidates across metabolic, neurologic, and other disorders.
Is Ultragenyx profitable?
+
No. As of May 2026 Ultragenyx was not profitable, reporting a net loss of about $575 million in 2025 as it funds heavy research and development. Management has stated a goal of reaching profitability in 2027, though that is an objective rather than a certainty.
How much revenue does Ultragenyx generate?
+
Full-year 2025 revenue was about $673 million, roughly 20% growth, and first-quarter 2026 revenue was about $136 million. The company reaffirmed 2026 guidance of $730 million to $760 million, which excludes any potential new product launches.
Walnut is informational, not investment advice, and gives no verdict on RARE. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.
Guides that feature RARE
RARE is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.